Novartis Hopes To Broaden SMA Patient Pool After Intrathecal Zolgensma Success

The Swiss giant’s blockbuster gene therapy is currently only administered intravenously into patients with spinal muscular atrophy under two years of age. Its intrathecal candidate, called OAV-101, has just passed a Phase III test which could expand its use in children and young adults.

Surgical doctor looking at radiological spinal x-ray film for medical diagnosis on patient’s health on spine disease, bone cancer illness, spinal muscular atrophy, medical healthcare concept
• Source: Shutterstock

It has been a bumpy road but Novartis has made a major leap in advancing an intrathecal version of its spinal muscular atrophy (SMA) gene therapy Zolgensma which would significantly expand the number of people who would be eligible to receive the transformational drug.

More from Gene Therapies

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy

 

Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.

Atsena To Advance XLRS Gene Therapy With Latest Funding Round

 

The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.

Stock Watch: Are Gene Therapy Prices Too High For Success?

 
• By 

The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.

Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’

 

The founder and CEO of Ultragenyx talked with Scrip as the company approaches a pivotal data readout and awaits US FDA action on its first gene therapy.

More from Therapy Areas

AbbVie On A STEAP Learning Curve In ADCs

 

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By 

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure

 

The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.